Keytruda wins FDA approval in head and neck cancer
admin 12th June 2019 Uncategorised 0More: Keytruda wins FDA approval in head and neck cancer Source: News
read more
More: Keytruda wins FDA approval in head and neck cancer Source: News
read moreDrugmakers often find themselves at odds with Britain’s drug-cost watchdogs; just consider Vertex and its standoff with NHS on cystic fibrosis treatments. Now, pharma’s trade group there has rolled out a social media campaign talking up the ways pharma and
read moreThe Vault is a content management system and suite of applications specifically built for life sciences that eradicates the need for multiple programmes. More: Veeva announce new products at annual R&D Summit Source: News
read moreThe path to success for Eli Lilly and Incyte’s rheumatoid arthritis drug Olumiant in the U.S. has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Could new long-term safety data—and a potential label expansion—help turn
read moreCatalyst isn’t shying away from controversy. The company that made headlines for its $375,000 price on a long-available drug has now sued the FDA for approving a potential competitor. More: It's Catalyst vs. the feds as tiny drugmaker sues FDA
read moreThe new Chair of the 2019 PharmaTimes Communications Team of the Year executive steering group (ESG) reveals why in-house practitioners and agencies should enter into this unique, industry renowned competition. More: Communications Team of the Year Chair explains what makes
read more© 1994 - 2026 B.M. Pharmaceuticals